Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Interpace Diagnostics Group Inc (NASDAQ:IDXG)

1.79
Delayed Data
As of May 26
 -0.08 / -4.28%
Today’s Change
0.70
Today|||52-Week Range
19.80
-59.32%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Services to the Health Industry
MARKET CAP
$16.4M

Company Description

Interpace Diagnostics Group, Inc. provides commercialization services to biopharmaceutical companies. It focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for patient diagnosis and management. The company offers commercialized molecular tests which include PancraGen, ThyGenX, and ThyraMIR. PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.

Contact Information

Interpace Diagnostics Group, Inc.
Morris Corporate Center 1 Building A
Parsippany New Jersey 07054
P:(855) 776-6419
Investor Relations:

Employees

Shareholders

Other institutional6.06%
Mutual fund holders1.06%
Individual stakeholders0.78%

Top Executives

Jack E. StoverPresident, Chief Executive Officer & Director
Glenn GershonSenior Vice President-Operations
James EarlyChief Financial Officer
Sydney D. FinkelsteinChief Scientific Officer
Sara A. JacksonVice President-Clinical Development